Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis
Authors:
- 6 November 2019
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (12) , 1126-1136
Abstract
Study Objectives: To compare the effectiveness of different taxane‐containing regimens and to identify the best strategy for the treatment of human epidermal growth factor receptor 2 (HER2)‐negative metastatic breast cancer (MBC).Design: Network meta‐analysis of 20 randomized controlled trials (RCTs).Patients: A total of 6577 patients with HER2‐negative MBC who received treatment (20 different regimens) with taxanes (paclitaxel [4267 patients] or docetaxel [2310 patients]).Measurements and Main Results: The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched (through March 2019) for RCTs that evaluated any taxane‐containing regimens for the treatment of HER2‐negative MBC. A network meta‐analysis in a Bayesian framework was performed using the random‐effects model. We compared the surface under the cumulative ranking (SUCRA) curve for each regimen. Overall, paclitaxel‐based combinations were superior to paclitaxel alone in objective response rate (ORR) (odds ratio 1.60, 95% credible interval [CrI] 1.15–2.16) and overall survival (OS) (hazard ratio 1.08, 95% CrI 1.01–1.15). Docetaxel‐based combinations were also superior to paclitaxel alone in ORR. Among the paclitaxel‐based regimens, based on the results of SUCRA, paclitaxel + bevacizumab + capecitabine was likely to be the most efficacious in improving ORR, OS, and progression‐free survival (PFS), whereas paclitaxel + gemcitabine was likely to be the most efficacious in 1‐year OS rate. Among the docetaxel‐based regimens, based on the results of SUCRA, docetaxel + gemcitabine was likely to be the most efficacious in improving PFS and OS.Conclusion: These findings demonstrated that paclitaxel‐based combinations can provide significant improvement in ORR and OS compared with paclitaxel alone. The regimens of paclitaxel + bevacizumab + capecitabine, docetaxel + gemcitabine, and paclitaxel + gemcitabine may be superior to other regimens for the treatment of HER2‐negative MBC.Keywords
Funding Information
- National Natural Science Foundation of China (81773828, 81273600)
- Natural Science Foundation of Hebei Province (C2011206145, C2018206297)
This publication has 38 references indexed in Scilit:
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patientsAnnals of Oncology, 2013
- Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatmentsBMC Cancer, 2013
- Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2011
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJournal of Clinical Oncology, 2010
- SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancerAnnals of Oncology, 2010
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast CancerJournal of Clinical Oncology, 2009
- Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2008
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentJournal of Clinical Oncology, 2008